BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37591940)

  • 21. FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2.
    Fleskens V; Mokry M; van der Leun AM; Huppelschoten S; Pals CE; Peeters J; Coenen S; Cardoso BA; Barata JT; van Loosdregt J; Coffer PJ
    Oncogene; 2016 Aug; 35(31):4141-8. PubMed ID: 26686090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
    McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
    Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromatin looping defines expression of TAL1, its flanking genes, and regulation in T-ALL.
    Zhou Y; Kurukuti S; Saffrey P; Vukovic M; Michie AM; Strogantsev R; West AG; Vetrie D
    Blood; 2013 Dec; 122(26):4199-209. PubMed ID: 24200685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia.
    Sanda T; Leong WZ
    Exp Hematol; 2017 Sep; 53():7-15. PubMed ID: 28652130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The enhancer RNA
    Tan SH; Leong WZ; Ngoc PCT; Tan TK; Bertulfo FC; Lim MC; An O; Li Z; Yeoh AEJ; Fullwood MJ; Tenen DG; Sanda T
    Blood; 2019 Jul; 134(3):239-251. PubMed ID: 31076442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia.
    Benyoucef A; Palii CG; Wang C; Porter CJ; Chu A; Dai F; Tremblay V; Rakopoulos P; Singh K; Huang S; Pflumio F; Hébert J; Couture JF; Perkins TJ; Ge K; Dilworth FJ; Brand M
    Genes Dev; 2016 Mar; 30(5):508-21. PubMed ID: 26944678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL.
    Ono Y; Fukuhara N; Yoshie O
    J Biol Chem; 1997 Feb; 272(7):4576-81. PubMed ID: 9020185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alteration of CTCF-associated chromatin neighborhood inhibits TAL1-driven oncogenic transcription program and leukemogenesis.
    Li Y; Liao Z; Luo H; Benyoucef A; Kang Y; Lai Q; Dovat S; Miller B; Chepelev I; Li Y; Zhao K; Brand M; Huang S
    Nucleic Acids Res; 2020 Apr; 48(6):3119-3133. PubMed ID: 32086528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Helix-loop-helix (E2-5, HEB, TAL1 and Id1) protein interaction with the TCRalphadelta enhancers.
    Bernard M; Delabesse E; Smit L; Millien C; Kirsch IR; Strominger JL; Macintyre EA
    Int Immunol; 1998 Oct; 10(10):1539-49. PubMed ID: 9796921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.
    Draheim KM; Hermance N; Yang Y; Arous E; Calvo J; Kelliher MA
    Oncogene; 2011 Mar; 30(10):1252-60. PubMed ID: 21057528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-146b negatively regulates migration and delays progression of T-cell acute lymphoblastic leukemia.
    Correia NC; Fragoso R; Carvalho T; Enguita FJ; Barata JT
    Sci Rep; 2016 Aug; 6():31894. PubMed ID: 27550837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia.
    Mets E; Van der Meulen J; Van Peer G; Boice M; Mestdagh P; Van de Walle I; Lammens T; Goossens S; De Moerloose B; Benoit Y; Van Roy N; Clappier E; Poppe B; Vandesompele J; Wendel HG; Taghon T; Rondou P; Soulier J; Van Vlierberghe P; Speleman F
    Leukemia; 2015 Apr; 29(4):798-806. PubMed ID: 25231743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. microRNAs regulate TAL1 expression in T-cell acute lymphoblastic leukemia.
    Correia NC; Melão A; Póvoa V; Sarmento L; Gómez de Cedrón M; Malumbres M; Enguita FJ; Barata JT
    Oncotarget; 2016 Feb; 7(7):8268-81. PubMed ID: 26882564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential genomic targeting of the transcription factor TAL1 in alternate haematopoietic lineages.
    Palii CG; Perez-Iratxeta C; Yao Z; Cao Y; Dai F; Davison J; Atkins H; Allan D; Dilworth FJ; Gentleman R; Tapscott SJ; Brand M
    EMBO J; 2011 Feb; 30(3):494-509. PubMed ID: 21179004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events.
    Mendes RD; Sarmento LM; Canté-Barrett K; Zuurbier L; Buijs-Gladdines JG; Póvoa V; Smits WK; Abecasis M; Yunes JA; Sonneveld E; Horstmann MA; Pieters R; Barata JT; Meijerink JP
    Blood; 2014 Jul; 124(4):567-78. PubMed ID: 24904117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells.
    Cardoso BA; de Almeida SF; Laranjeira AB; Carmo-Fonseca M; Yunes JA; Coffer PJ; Barata JT
    Leukemia; 2011 Oct; 25(10):1578-86. PubMed ID: 21647153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia.
    Palomero T; Odom DT; O'Neil J; Ferrando AA; Margolin A; Neuberg DS; Winter SS; Larson RS; Li W; Liu XS; Young RA; Look AT
    Blood; 2006 Aug; 108(3):986-92. PubMed ID: 16621969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
    Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
    Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross talk between expression of the human T-cell leukemia virus type 1 Tax transactivator and the oncogenic bHLH transcription factor TAL1.
    Terme JM; Wencker M; Favre-Bonvin A; Bex F; Gazzolo L; Duc Dodon M; Jalinot P
    J Virol; 2008 Aug; 82(16):7913-22. PubMed ID: 18495761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.
    Mansour MR; Abraham BJ; Anders L; Berezovskaya A; Gutierrez A; Durbin AD; Etchin J; Lawton L; Sallan SE; Silverman LB; Loh ML; Hunger SP; Sanda T; Young RA; Look AT
    Science; 2014 Dec; 346(6215):1373-7. PubMed ID: 25394790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.